Navigation Links
Breckenridge Pharmaceutical Signs Long Term Agreement with Helm AG (Hamburg, Germany)
Date:1/7/2008

BOCA RATON, Fla., Jan. 7 /PRNewswire/ -- Breckenridge announced today that it has entered into an agreement with Helm AG to develop and manufacture a generic tablet ANDA product. Breckenridge expects to file an ANDA with the FDA in January 2008. Upon approval by the FDA, Helm AG will supply and Breckenridge will market and distribute the product on an exclusive basis.

Under terms of the agreement, Breckenridge will submit an ANDA to the U.S. Food and Drug Administration (FDA) for the product which as been developed by Helm AG. The product currently shows U.S. sales of approximately $800 million.

About Breckenridge:

Breckenridge Pharmaceutical is a privately held pharmaceutical marketing, research and development company founded in 1983 that markets a broad range of ValuBrand(TM) and Generic prescription products in many therapeutic categories. The Breckenridge label is recognized by Wholesalers, Distributors, Chains, and Managed Care Accounts, as well as Retail Pharmacies nationwide. The company markets over 100 products, more than 150 sku's, in a variety of dosage forms including: Tablets, Capsules, Soft Gel Capsules, Liquids, Suspensions and Topical preparations. http://www.bpirx.com

About Helm AG:

Helm AG is an international chemical and pharmaceutical organization and a multifunctional marketing group which operates as a link between producers and industrial end users.

With branch offices and participations in 32 countries HELM provides a wide range of services including marketing, distribution, production, logistics, generic development and registration. http://www.helmag.com

For Further Information, please contact:

Breckenridge Pharmaceutical Helm New York, Inc.

Larry Lapila, Vice President Boy Ehlers, Vice President

Business Development Pharmaceutical Division

TEL: 860-828-8140 TEL: 732-981-1160

FAX: 860-828-8142 FAX: 732-981-0965

e-Mail: llapila@bpirx.com behlers@helmnewyork.com


'/>"/>
SOURCE Breckenridge Pharmaceutical
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Patient-Centric Healthcare Study Reveals Key Insights for Pharmaceutical Marketers
2. KV Pharmaceutical Company Announces NYSE Listing Extension
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
4. Pharmaceutical Sales: Best Practices for Pharmaceutical Sales Success
5. NPS Pharmaceuticals to Present at the JPMorgan 26th Annual Healthcare Conference on January 9, 2008
6. Gerresheimer Expands its Pharmaceutical Plastic Operations Into Southern Europe and South America
7. ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily)
8. Law Offices of Howard G. Smith Announces 25 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Threshold Pharmaceuticals, Inc.
9. Idenix Pharmaceuticals to Present at the JP Morgan 26th Annual Healthcare Conference
10. Cogentus Pharmaceuticals Completes $62.5 Million Private Financing
11. Par Pharmaceutical Reports Third-Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... products to meet the demand of today’s consumer and regulatory authorities worldwide. From ... probiotic experts and tested to meet the highest standard. , These products ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader ... a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were ... 11, 2017. , The annual award competition recognizes editorial and design excellence across a ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), ... solutions, today announced that its MyDario product is expected to appear on ... for when The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. ... ...
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
Breaking Medicine Technology: